Erik Wiklund

Erik Wiklund

Company: Targovax ASA

Job title: Chief Executive Officer



Panel Discussion – Evaluating Combination Therapies to Maximise Anti-Tumour Immune Activity 4:00 pm

• What is the ideal combination strategy for neoantigen vaccines? • What are the best combination therapies that maximise T cell responses and efficacy? • How to identify a clear biologic effect caused by combination • Improving clinical efficacy through immunotherapy combinationsRead more

day: Day Two

Uncovering the Benefits of Personalised Vaccines in a Clinical Setting 10:00 am

• Uncovering features of peptide anti-cancer vaccines that makes this class attractive • Proving benefits of peptide cancer vaccines in the clinic- which setting? • Discussing considerations of dose and scheduleRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.